Rapport Therapeutics, Inc. (RAPP) Stock Price & How to Invest

Rapport Therapeutics (Nasdaq: RAPP) is a clinical-stage biotechnology company building small-molecule precision medicines for neurological and psychiatric conditions. Its platform is based on receptor associated proteins (RAPs), and its lead candidate RAP-219 is a negative allosteric modulator that selectively targets TARP gamma-8, a protein expressed only in specific brain regions such as the hippocampus where focal seizures originate. That selectivity is meant to differentiate RAP-219 from broad AMPA antagonists like Eisai's perampanel, which act throughout the brain and carry tolerability limits. The company went public in June 2024 at $17 per share, raising roughly $174 million, and is advancing RAP-219 across focal epilepsy, bipolar mania, and peripheral neuropathic pain.

The investment picture is a classic pre-commercial biotech profile: no product revenue, ongoing net losses, and a valuation driven by clinical milestones rather than fundamentals. In April 2026 Rapport reported Phase 2a follow-up data in drug-resistant focal onset seizures showing roughly a 90% median reduction in clinical seizures with sustained effect, which supported an accelerated move into Phase 3. The company reported about $476.8 million in cash and short-term investments as of March 31, 2026, funding operations into the second half of 2029, so the near-term risk is scientific and regulatory rather than financial. Bipolar mania topline data is expected in Q4 2026 and additional epilepsy trials extend into 2027.

As a clinical-stage biotech, Rapport has no approved products and no product revenue, so the equity is highly sensitive to trial outcomes. Phase 2a results, while encouraging, come from small patient numbers and do not guarantee success in larger, longer Phase 3 trials, where efficacy or safety signals can weaken. The company depends heavily on a single molecule, RAP-219, meaning a failure in one indication can cast doubt across the pipeline. Even with runway into 2H 2029, eventual commercialization or additional trials may require dilutive financing. Regulatory delays, competition from entrenched anti-seizure therapies, and typical biotech volatility all add meaningful uncertainty.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Rapport Therapeutics, Inc.'s investor relations page or your broker.

• Market cap: ~$1.8B
• Cash & short-term investments (Mar 2026): ~$477M
• Q1 2026 net loss: ~$20M
• Q1 2026 collaboration revenue: ~$20M
• Cash runway: Into 2H 2029
• Shares outstanding: ~48M

Rapport is pre-commercial, so traditional valuation multiples do not apply and the market prices it on pipeline probability and cash runway. The roughly $1.8 billion market cap against about $477 million in cash implies investors are assigning substantial value to RAP-219's clinical prospects. The company reported collaboration revenue during Q1 2026 alongside a net loss, but ongoing R&D spending will keep it loss-making for the foreseeable future.

There are three common ways to get RAPP exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so RAPP sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where RAPP fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

RAPP is a single-asset neuroscience bet: strong early RAP-219 data and a deep cash cushion into 2H 2029, but the outcome hinges on Phase 3 trials that are years from resolving.

Whether RAPP is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RAPP a buy?, and where the stock could go from here in the RAPP stock forecast.

For income investors, whether RAPP pays a dividend and how the payout looks is covered in does RAPP pay a dividend?